|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 356.80 INR | +1.05% |
|
-0.78% | -13.37% |
| 07/03 | Pinnacle Life Science Pvt. Ltd announced that it expects to receive INR 100 million in funding from Aarti Drugs Limited | CI |
| 04/02 | Aarti Drugs Limited, Q3 2026 Earnings Call, Feb 04, 2026 |
Company Valuation: Aarti Drugs Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 64,755 | 39,725 | 31,280 | 39,886 | 31,240 | 32,565 | - | - |
| Change | - | -38.65% | -21.26% | 27.51% | -21.68% | 4.24% | - | - |
| Enterprise Value (EV) | 64,755 | 39,725 | 31,280 | 39,886 | 31,240 | 32,565 | 32,565 | 32,565 |
| Change | - | -38.65% | -21.26% | 27.51% | -21.68% | 4.24% | 0% | 0% |
| P/E ratio | 23.1x | 19.4x | 18.8x | 23.4x | 18.5x | 17.8x | 14.4x | 12.2x |
| PBR | 7.09x | 3.83x | 2.62x | 3.11x | 2.27x | 2.15x | 1.93x | 1.72x |
| PEG | - | -0.7x | -1x | 7.13x | -16.35x | 1.98x | 0.6x | 0.7x |
| Capitalization / Revenue | 3.01x | 1.6x | 1.15x | 1.58x | 1.31x | 1.25x | 1.1x | 0.98x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.25x | 1.1x | 0.98x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 10.2x | 8.13x | 7.01x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 12.7x | 9.97x | 8.47x |
| EV / FCF | 0x | -0x | -0x | 0x | 0x | 35.7x | 31.4x | 27x |
| FCF Yield | 1.03% | -1.86% | -0.97% | 3.32% | 2.16% | 2.8% | 3.19% | 3.7% |
| Dividend per Share 2 | 2.5 | 1 | - | 1 | - | 4 | 5.4 | 7.3 |
| Rate of return | 0.36% | 0.23% | - | 0.23% | - | 1.12% | 1.51% | 2.05% |
| EPS 2 | 30.09 | 22.12 | 17.97 | 18.56 | 18.35 | 20 | 24.7 | 29.2 |
| Distribution rate | 8.31% | 4.52% | - | 5.39% | - | 20% | 21.9% | 25% |
| Net sales 1 | 21,548 | 24,886 | 27,160 | 25,286 | 23,870 | 26,066 | 29,472 | 33,182 |
| EBITDA 1 | 4,371 | 3,294 | 3,056 | 3,165 | 2,871 | 3,206 | 4,008 | 4,645 |
| EBIT 1 | 3,872 | 2,794 | 2,553 | 2,650 | 2,313 | 2,569 | 3,266 | 3,843 |
| Net income 1 | 2,804 | 2,050 | 1,663 | 1,714 | 1,682 | 1,822 | 2,253 | 2,666 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 694.80 | 429.00 | 337.80 | 433.85 | 339.80 | 356.80 | 356.80 | 356.80 |
| Nbr of stocks (in thousands) | 93,200 | 92,600 | 92,600 | 91,935 | 91,935 | 91,270 | - | - |
| Announcement Date | 15/05/21 | 09/05/22 | 29/04/23 | 03/05/24 | 06/05/25 | - | - | - |
1INR in Million2INR
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 17.66x | - | - | 1.13% | 35Cr | ||
| 29.39x | 11.07x | 22.23x | 0.66% | 89TCr | ||
| 25.78x | 6x | 16.34x | 2.18% | 59TCr | ||
| 24.73x | 6.77x | 13.58x | 3.04% | 40TCr | ||
| 17.77x | 4.33x | 10.71x | 3.05% | 34TCr | ||
| 24.42x | 5.09x | 14.09x | 1.71% | 30TCr | ||
| 21.17x | 5.7x | 14.1x | 2.84% | 30TCr | ||
| 27.16x | 4.76x | 14.89x | 2.9% | 29TCr | ||
| 25.41x | 6.42x | 11.43x | 2.66% | 20TCr | ||
| 20.24x | 6.16x | 11.14x | 2.23% | 18TCr | ||
| Average | 23.37x | 6.25x | 14.28x | 2.24% | 34.9TCr | |
| Weighted average by Cap. | 25.10x | 7.05x | 15.92x | 2.08% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- AARTIDRUGS Stock
- Valuation Aarti Drugs Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















